Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Inhibition of MGAT2 modulates fat‐induced gut peptide release and

Pharmacological characterization of a series of aryl-sulfonamide

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Pharmacotherapies of NAFLD: updated opportunities based on

Efficacy and safety of an orally administered DGAT2 inhibitor

Therapeutic Strategies for Metabolic Diseases: Small‐Molecule

NASH Target Development Service for DAG O-Acyltransferase (DGAT

Full article: Patent landscape for discovery of promising